SLS-006: Modified-release Dopamine Partial Agonist For CNS Indications
SLS-006 is well positioned for Phase III clinical trials for monotherapy and adjunctive therapy in Early/Late stage Parkinson’s Disease
SLS-006 is a potent clinically-validated partial agonist of the dopamine D2 receptor with a large preclinical and clinical database
Existing clinical data
(>300 patients)
show statistical significance in Parkinson’s Disease
Potential improved profile provided by partial agonism
- Restores dopamine activity in dopamine-deficient areas of the brain
- Avoids over-stimulation of dopamine system in unaffected brain areas
- Reduces side effects such as nausea, somnolence, hallucinations, dyskinesia
- Potential for shorter titration
SLS-006-201: Robust Efficacy in PD
Andree TH, Brennan J, Hansard M, et al. Aplindore, a novel potent dopamine D2 receptor partial agonist is efficacious as a monotherapy or when combined with L-DOPA in treating motor disabilities in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated marmoset, a non-human model of Parkinson's Disease. Program No. 693.12/N14. 2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2007. https://bit.ly/2PDjSeV.
SLS-006-201: Safety in PD
SLS-006-201: Adverse Events
SLS-006: Has the Potential to be a Broad Spectrum NCE in PD
Large unmet need
1.5 MM patients in US, EU and Japan utilize poly-pharmacy before using L-Dopa
Chronic usage
Current treatments are not curative
More efficacious drug
Placebo adjusted efficacy on UPDRS Part III similar to L-Dopa
Better side-effect profile
Most marketed drugs have SAEs
in vivo pre-clinical pharmacology
Animal studies support SLS-006 utility as monotherapy or in combination with LDOPA in treating motor disabilities seen in patients with Parkinson’s Disease
Broad-spectrum activity
SLS-006 exhibits activity in early stage (as monotherapy) as well as adjunctive therapy with reduced dose of L-Dopa in late stage PD patients